Business
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also help reduce overall healthcare costs.
About this update from Penumbra, Inc.
[{"type":"text","content":"ALAMEDA, Calif., April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also help reduce overall healthcare costs.","length":470,"tagName":"p"},{"type":"image","alt":"Seven New Data Sets Demonstrate Penumbra’s Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits","displaySize":"","headline":null,"caption":"Seven New Data Sets Demonstrate Penumbra’s Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/77ad5bc36142c692398700f080ac9559"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mjZpdhv527Yk7rgacPzAnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/77ad5bc36142c692398700f080ac9559","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2655815/CAVT.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""With this growing body of evidence across several disease states, we are continuously demonstrating the wide-ranging impact CAVT can have as a frontline option on patient outcomes, quality of life and resource utilization in the healthcare system," said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. "This extensive research and innovation in clot management underscores our commitment to save lives, improve patient outcomes and positively impact healthcare economics."","length":511,"tagName":"p"},{"type":"text","content":"STRIKE-PE Continued to Showcase CAVT's Speed, Safety and Simplicity in the Treatment of PE","length":94,"tagName":"p"},{"type":"text","content":"All four presentations featuring interim results of STRIKE-PE demonstrated CAVT is a safe, fast and effective procedure for the treatment of pulmonary emboli...